Muller, Marjolein
Scafa, Stefano
Hanafi, Ibrahem
Varescon, Camille
Palmisano, Chiara
van der Gaag, Saskia
Zutt, Rodi
van der Gaag, Niels A.
Hoffmann, Carel F. E.
Bloch, Jocelyne
Jiménez, Mayte Castro
Bally, Julien F.
Capetian, Philipp
Isaias, Ioannis U.
Moraud, Eduardo M.
Contarino, M. Fiorella
Funding for this research was provided by:
HORIZON EUROPE European Innovation Council (101070865 (Minigraph))
HORIZON EUROPE European Innovation Council (101070865 (Minigraph))
Deutscher Akademischer Austauschdienst
Deutsche Forschungsgemeinschaft (424778381 - TRR 295)
Fondazione Europea Ricerca Biomedica
Fondazione Pezzoli per la Malattia di Parkinson
School of Medicine, New York University
Marlene and Paolo Fresco Institute for Parkinson's and Movement Disorders
NextGenerationEU (NRRP M6C2 - Investment 2.1)
Article History
Received: 26 November 2024
Accepted: 23 July 2025
First Online: 8 August 2025
Competing interests
: M.F.C. is an independent consultant for research and educational issues of Medtronic and Boston Scientific (all fees to institution), is an independent consultant for research by INBRAIN (all fees to institution), and received speaking fees for: ECMT (CME activity). CP received research fundings from Medtronic for a project unrelated to the current study. IUI is a Newronika S.p.A. consultant and shareholder. IUI received lecture honoraria and research fundings from Medtronic Inc., Newronika S.p.A. and Boston Scientific. IUI is Adjunct Professor at the Department of Neurology, NYU Grossman School of Medicine. JFB received speaker’s honoraria from Medtronic and AbbVie, unrelated to this research. J.B. is shareholder of ONWARD Medical B.V., a company developing products for stimulation of the spinal cord, not related to this research. All other authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.